Jodol

Quick links to important sections

Jodol

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jodol

Quick Facts

Property Description
Active Ingredient Ondansetron
Form Tablets (ODT, film-coated), Oral Solution, Injection
Pharmacological Class Selective 5-HT3 Receptor Antagonist
General Purpose Prevention of Nausea and Vomiting
Origin Synthetic Compound (Carbazole derivative)

What Type of Medicine is Jodol? (Classification and Identity)

Jodol is a prescription-only pharmaceutical preparation defined by its active ingredient, Ondansetron. It belongs to the broader antiemetic drug group, which comprises medicines used to prevent nausea and vomiting, and is specifically classified as a selective 5-HT3 receptor antagonist. This agent is a synthetic compound, manufactured as a carbazole derivative, and is not derived from natural sources. This classification is clinically recognized for its potent and focused action compared to older, less selective agents. Ondansetron acts by specifically targeting and inhibiting the 5-HT3 receptor. This mechanism helps stop the body's key chemical signals responsible for triggering the vomiting reflex.


What is the Composition and General Purpose of Jodol? (Form and Benefit)

The core composition of Jodol is its single active ingredient, Ondansetron, often present in a stable form such as Ondansetron hydrochloride dihydrate, along with pharmaceutical excipients. Ondansetron is considered an essential medicine, which reflects its therapeutic importance and a status consistent with pharmacological data. This underlines its role as a vital agent for supportive care. This medicine is available in multiple dosage forms to suit various clinical needs, including film-coated tablets, specialized orally disintegrating tablets (ODT), an oral solution, and an aqueous solution for injection. This variety of forms dictates the respective route of administration, which can be oral, intravenous (IV), or intramuscular (IM). The physiological action of Ondansetron is to disrupt the chemical signaling that triggers emesis by highly selective antagonism of the 5-HT3 receptor. This focused blockade provides the key therapeutic benefit of mitigating and suppressing the body’s nausea and vomiting reflexes.

Regulatory References

  1. WHO Essential Medicines List Entry

What side effects are possible with Jodol?

Possible Side Effects and Safety Information for Jodol

Jodol is associated with a range of documented side effects, including a Boxed Warning required by regulatory authorities concerning the risk of serious, disabling, and potentially permanent adverse reactions affecting the musculoskeletal, nervous, and central nervous systems.


Documented Adverse Reactions

Classification Common Reactions Serious/Clinically Significant Reactions
Gastrointestinal Nausea, Diarrhea Severe diarrhea (Clostridium difficile associated)
Nervous System Headache, Dizziness, Trouble sleeping (Insomnia) Peripheral neuropathy (numbness, tingling, pain), Confusion, Hallucinations, Suicidal thoughts, Anxiety, Depression
Musculoskeletal Muscle pain, Joint pain Tendinitis, Tendon rupture, Worsening of Myasthenia Gravis (a muscle weakness disorder)
Cardiac QT interval prolongation (a heart rhythm abnormality), Abnormal/irregular heartbeat
Immune/Skin Skin rash Anaphylaxis/Severe hypersensitivity, Severe skin reactions, Photosensitivity/Phototoxicity

Key Safety Limitations and Considerations

  • Permanent Adverse Effects: Serious side effects involving the tendons, nerves, and central nervous system can occur within hours to weeks of starting treatment and have been reported to continue for prolonged periods after discontinuation.
  • Restricted Use: Due to the risk of these disabling effects, the use of Jodol is reserved for patients who have no alternative treatment options for certain uncomplicated infections (e.g., acute bacterial sinusitis, uncomplicated urinary tract infections, acute bacterial exacerbation of chronic bronchitis).
  • Population-Specific Risks: The drug is generally contraindicated in patients with a history of hypersensitivity to Jodol or other drugs in its class. Caution is also warranted in patients with pre-existing cardiac risk factors due to the potential for heart rhythm abnormalities.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented effects and mandated actions concerning overdose, as stated in government regulatory documents.

Element Official Regulatory Statement
Documented Manifestations Officially listed signs of overdose include transient visual disturbances (including temporary blindness/amaurosis), severe constipation, hypotension (low blood pressure), and fainting (syncope). Cases consistent with Serotonin Syndrome have been reported, particularly in children [3.1, 1.6].
Severe Outcomes The most critical risk is cardiotoxicity, which may manifest as QT interval prolongation on an electrocardiogram (ECG). This can lead to potentially fatal arrhythmias, including Torsades de Pointes (TdP) and Cardiac Arrest [1.7, 2.3].
Emergency Action Required Seek immediate medical attention for suspected overdose [1.6, 1.7]. If an overdose occurs, continuous ECG monitoring is required for assessment of cardiac activity due to the risk of life-threatening heart rhythm abnormalities [1.7].
Management Treatment is entirely symptomatic and supportive. No specific antidote for this medication is known or documented in the official regulatory labeling [3.1].
Population Note Pediatric patients who have ingested an estimated overdose (exceeding 5 mg/kg in some reports) have experienced symptoms consistent with Serotonin Syndrome and require close monitoring [3.1].

The regulatory profile defines overdose as a potentially critical event due to the serious risk of cardiac electrical abnormalities. Consequently, the regulator mandates immediate medical intervention and continuous cardiac monitoring to manage the potential for severe outcomes, such as Torsades de Pointes. As the official labeling confirms the lack of a known specific antidote, the entire clinical approach described is focused on providing aggressive supportive and symptomatic care.

Therapeutic Uses of Jodol

Jodol is commonly used across conditions presenting with acute episodes where additional management of discomfort and symptom intensity is required. Its primary therapeutic purpose is considered relevant for providing short-term symptomatic assistance and supportive relief in specific clinical scenarios marked by heightened systemic burden.

Supportive Relief for Systemic Symptom Patterns

Jodol, in its oral form, may be part of symptomatic management for symptoms related to systemic imbalance, particularly those involving heightened physiological activity. This application is applied in clinical settings that involve acute or unstable symptom patterns.

Management of Challenging Symptom Clusters

The medication is commonly used to help with symptom clusters that may interfere with daily functioning. It is applied during phases when a patient experiences increased distress or discomfort, often in conditions characterized by periods of heightened symptoms. By helping to manage symptom intensity, it contributes to improved day-to-day comfort and supports patients during episodes of heightened discomfort.

“Jodol is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.”

Quick Fact: Relief for Heightened Symptoms Jodol supports patients during difficult episodes by easing the overall symptom burden and helping to manage the intensity of manifestations during acute phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Jodol?

This section describes the official population eligibility and non-eligibility rules for Jodol (Ondansetron) as documented in governmental regulatory sources.

Contraindicated Populations

Category Regulatory Status
Hypersensitivity Contraindicated in patients with known hypersensitivity to the drug or any component.
Apomorphine Use Contraindicated for patients concurrently receiving apomorphine.
Congenital Long QT Syndrome Use must be avoided due to the risk of QT prolongation.

Age and Condition-Based Restrictions

Category Eligibility Rule
Pediatric Use (Oral) Safety and efficacy are not established in children younger than 4 years of age for CINV prophylaxis.
Pediatric Use (Injection) Approved for patients aged geq 1 month (for PONV) or geq 6 months (for CINV).
Severe Hepatic Impairment Use is restricted; the total daily dose must not exceed 8 mg.
Pregnancy Not recommended during the first trimester of pregnancy.

Official regulations state that adults are eligible under standard conditions, and no dosage adjustment is required for renal impairment or geriatric patients. However, Jodol may only be used conditionally in patients with electrolyte abnormalities or those at risk of subacute intestinal obstruction, and these conditions require special attention as stated in the official labeling.

What should I know about interactions with other medicines?

Jodol can interact with a variety of other substances, potentially altering its effect or increasing the risk of adverse reactions. It is crucial to inform your healthcare provider about all medicines, over-the-counter drugs, herbal supplements, and food products you are currently using.

Drug-Drug Interactions

Co-administration of Jodol with certain medicines can lead to clinically significant interactions. Key substances to consider include:

  • Central Nervous System (CNS) Depressants: Combining Jodol with other medications that slow brain activity (e.g., alcohol, sedatives, benzodiazepines, other opioids, muscle relaxants, some antidepressants) may result in severe drowsiness, breathing difficulties, coma, or even death.
  • Cytochrome P450 Enzyme Inhibitors/Inducers: Medicines that affect the liver enzymes responsible for breaking down Jodol can either increase its concentration (and risk of side effects) or decrease its effectiveness. Examples of inhibitors include certain antifungals and antivirals.
  • Serotonergic Drugs: Simultaneous use with drugs that increase serotonin levels (e.g., SSRIs, SNRIs, triptans) may increase the risk of Serotonin Syndrome, a potentially life-threatening condition characterized by mental changes, rapid heart rate, and severe muscle stiffness.

Other Interactions

  • Alcohol: Avoid consuming alcohol entirely while taking Jodol, as this combination significantly enhances CNS depressant effects, leading to profound sedation and respiratory depression.
  • Grapefruit Juice: Grapefruit juice can interfere with the metabolism of Jodol, increasing the drug's levels in the body and heightening the risk of side effects. Avoid consuming this product during treatment.

Mechanism of Action

Jodol's mechanism relies on the precise, selective antagonism of the Serotonin Type 3 (5 -HT3) receptor, targeting a critical pathway that coordinates the physiological reflex of emesis. This action is executed via a dual approach.


Dual Interruption of the Emetic Signal Cascade

This domain covers the drug's action on 5 -HT3 receptors in both the gastrointestinal tract (peripheral) and the Chemoreceptor Trigger Zone (CTZ) (central). By blocking Serotonin (5 -HT) from activating receptors on the Vagus nerve and in the CTZ, the drug interrupts the neural signals that initiate and coordinate the vomiting response, contributing to the overall physiological regulation of the reflex.


Molecular Blockade of the 5 -HT3 Ion Channel

This domain addresses the fundamental molecular interaction where the drug competitively binds to the 5 -HT3 receptor. As the receptor is a ligand-gated ion channel, this blockade prevents the necessary ion flow. This results in the stabilization of the neuronal membrane and suppression of the electrical impulse that would otherwise signal the onset of emesis.


Pathway-Specific Mechanistic Limitations

This domain clarifies the scope of the mechanism by noting its high specificity for the 5 -HT3 pathway. Because the drug does not target other receptors, such as those for histamine or acetylcholine, the mechanism shows reduced physiological modulation against emetic triggers mediated by those alternative systems, such as signals related to motion sickness or certain types of delayed emesis.

Dosage and Administration Information

The administration of Jodol (Ondansetron) is based on strictly defined, time-sensitive protocols for prophylactic use. The medicine is administered via the oral route (tablets, solution, and orally disintegrating tablets), as well as by intravenous (IV) or intramuscular (IM) injection.

Usage patterns are inherently linked to the timing of the emetogenic event. For highly emetogenic chemotherapy, the protocol involves a single 24 mg oral dose or a multi-dose IV regimen, both administered before the start of the treatment. For preventing postoperative nausea and vomiting (PONV), a single dose of 16 mg orally or 4 mg via IV/IM injection is typically given close to the time of anesthesia or surgery. Following the acute stimulus, the drug is commonly continued as a short-term, cyclic maintenance regimen, often lasting one to five days.

Administration Guidelines

Condition Instructional Parameters
Preparation for IV Dosing IV doses over 8 mg must be diluted and administered via infusion over a minimum of 15 minutes.
Intake Condition Oral forms may be taken with or without food.
Special Populations Patients with severe hepatic impairment have a total daily dose ceiling that must not exceed 8 mg. No dose adjustment is required for renal impairment.
ODT Use Orally Disintegrating Tablets must be allowed to dissolve on the tongue and do not require water.

These instructions define the appropriate route, quantity, and time relationship for Jodol administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Jodol

The research base for Jodol consists primarily of Randomized Controlled Trials (RCTs) and Meta-Analyses that explored outcomes related to physical discomfort, such as vomiting frequency and patient-reported nausea.

Evidence for Major Uses

For Chemotherapy-Induced Nausea and Vomiting (CINV), studies explored how symptoms evolved in adults, as well as pediatric patients. Findings describe patterns where the study group was associated with measured outcomes for reduced emetic events during the acute phase (within 24 hours). However, the measured difference was often less prominent in the delayed phase (days 2–5).

For Postoperative Nausea and Vomiting (PONV), short-term trials explored symptoms in patients undergoing surgery. Observed patterns were associated with measured outcomes for reduced emetic events in the immediate short-term period.

Jodol was often evaluated as part of the broader 5-HT3 antagonist drug class in studies for Radiation-Induced Nausea and Vomiting (RINV), which explored outcomes capturing phases of heightened symptom activity in adults receiving radiotherapy.

Evidence in Special Populations and Limitations

Jodol was evaluated in clinical studies that included pediatric patients (as young as one month) and older adults for CINV and PONV. However, for many other specialized groups, the sample sizes were modest in the core efficacy trials, and comparative evidence is lacking for many comorbidity-defined groups.

Research focuses on short-term symptom changes, and follow-up durations were limited, typically only monitoring patients for the acute period. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding durability. The research provides insight into short-term changes, but research does not determine whether an individual will respond similarly over continuous use.

Key Studies & References

  1. Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults
  2. Management of vomiting in children and young people with gastroenteritis: ondansetron (NICE Evidence Summary)
  3. Public Assessment Report (PAR) Ondansetron Accord 2 mg/ml, solution for injection or infusion (EMA/MHRA related documentation on indications and populations)

Frequently Asked Questions (FAQ)

Common questions about Jodol (FAQ)

Q: How long does it usually take to notice effects after starting Jodol?

The timing of administration is critical for Jodol's use in preventing symptoms. Official prescribing information describes that the initial dose is given a specified period of time, such as 30 minutes, before the start of chemotherapy or immediately prior to anesthesia. This timing is consistent with the need for a preventative effect to be in place at the time of the triggering event.


Q: Does Jodol cause long-term problems or side effects?

Regulatory research primarily focuses on short-term symptom changes and has limited information regarding the durability of effects and long-term outcomes of continuous use. However, official safety information states that some serious adverse effects affecting the nervous or musculoskeletal systems may continue for prolonged periods after the medicine is stopped.


Q: Is Jodol known to interact with common pain relievers?

Co-administration with certain prescription pain relievers, particularly those that are in the opioid class like tramadol, has been examined in official documents. Using Jodol with pain medicines that also affect serotonin levels or cause central nervous system (CNS) depression may increase the risk of certain side effects, as noted in the drug's interaction warnings.


Q: How long does Jodol stay in the body after the last use?

The time the medicine takes to clear the body varies among individuals based on several factors. Official pharmacokinetic data describes the elimination half-life—the time it takes for half of the drug to be removed from the bloodstream—as approximately 5.7 hours in adults with typical liver function.


Q: Can Jodol affect sleep patterns?

Yes, official safety information reports that effects on the nervous system have been noted in clinical trials. These effects can include drowsiness, sedation, and difficulty sleeping (insomnia).


Q: Are there dietary restrictions or foods to avoid when taking Jodol?

Regulatory documents describe the need to avoid consuming alcohol entirely while taking Jodol due to the risk of enhancing sedative effects. Additionally, grapefruit juice should be avoided as it can interfere with how the body processes the medicine. Oral forms of Jodol may be taken with or without food.


Q: Is Jodol a widely studied drug?

Yes, the active ingredient has been extensively examined in randomized controlled trials and meta-analyses, particularly for its officially approved uses. This status is supported by its inclusion on the World Health Organization's Model List of Essential Medicines.


Q: Do different forms of Jodol (e.g., tablet vs liquid) have different instructions for use?

Yes, the specific preparation and use instructions vary significantly by the medicine’s form. For example, Orally Disintegrating Tablets (ODT) must dissolve on the tongue without water, while solutions for injection may require specific dilution and infusion times, as outlined in official administration guidelines.


Q: What information is available about Jodol's use during pregnancy or breastfeeding?

Official guidelines state that the medicine is not recommended during the first trimester of pregnancy. Limited available data suggests the amount present in human milk is low and that clinically relevant exposures for the infant are not expected.


Q: Does Jodol lose its effectiveness over time?

Research examining the prevention of chemotherapy-related symptoms noted that the measured difference in outcomes was often less prominent during the delayed phase of treatment (typically days 2–5) compared to the initial acute phase. This suggests the effects may differ over continuous use.


Q: What should someone know about Jodol before talking to a healthcare provider?

Official guidance requires patients to inform their healthcare provider about all current and planned medicines, herbal supplements, and pre-existing conditions (especially heart rhythm problems or severe liver impairment). The drug is contraindicated for use with apomorphine and requires attention due to the potential for QT prolongation and Serotonin Syndrome.


Q: Can Jodol be used by older adults?

Yes, in general. Clinical trials have found that safety and effectiveness patterns were similar for patients over 65 years of age compared to those under 65. Official prescribing information indicates that no dosage adjustment is typically recommended for older adults.


Q: Is it possible for Jodol to affect blood pressure?

Yes, changes in heart rate and rhythm, including fast or slow heartbeats, have been reported in official safety information. Severe hypotension (very low blood pressure) is also a known interaction when Jodol is used with the medicine apomorphine.


Q: Is Jodol considered a controlled substance?

No, the medicine is classified as a prescription-only drug (Rx-only) by regulatory agencies but is not scheduled as a controlled substance under US regulation.


Q: Does the time of day matter when taking Jodol?

The timing of administration is critical, but it is tied to the emetogenic event, not necessarily the time of day. The drug must be taken a specified period of time before the start of chemotherapy or immediately before surgery to achieve a preventative effect, as outlined in official guidelines.


Q: Are generic versions of Jodol available, and what's the difference?

Yes, generic versions of the active ingredient, Ondansetron, are widely available. Regulatory agencies ensure that generic drugs must meet the same rigorous quality, safety, and potency standards as the original brand-name medicine.


Q: How is Jodol generally classified by drug agencies?

Regulatory bodies classify Jodol as a prescription-only medicine (Rx-only) and a selective 5 -HT3 receptor antagonist. This classification defines its specific action on a chemical signaling pathway in the body. This status is also supported by its inclusion on the World Health Organization's Model List of Essential Medicines.


Q: Does Jodol have an impact on kidney or liver function?

Jodol is processed by the liver, and patients with severe hepatic impairment have a mandated total daily dose ceiling in official documents. While clearance is reduced in patients with severe renal impairment (kidney function), no dosage adjustment is typically required for that specific condition.


Q: How is Jodol different from an over-the-counter remedy for a similar concern?

Jodol is a prescription-only medicine classified as a selective 5 -HT3 receptor antagonist. This classification means it has a focused, specific mechanism of action that targets a key nausea-triggering chemical pathway and is used for conditions where an over-the-counter antiemetic may not be officially indicated or studied.


Q: Is Jodol commonly used in combination with other prescription medicines?

Yes, Jodol is frequently administered as part of combination regimens. This is particularly true for the prevention of nausea and vomiting associated with emetogenic chemotherapy and radiation therapy, where multiple medicines are used together to address symptoms.

How should Jodol be stored and disposed of?

Storage and Disposal Requirements

Jodol (Ondansetron) must be stored and disposed of according to official regulatory guidelines to maintain potency and prevent accidental exposure.

Storage Requirement Conditions
Temperature Controlled Room Temperature (20 C to 25 C). Do not freeze.
Protection Keep in the original, tightly closed container and protect from light and excessive moisture. Orally Disintegrating Tablets (ODT) must remain in their blister pack.
Safety Store securely out of the sight and reach of children.
Disposal Disposal should primarily be through a drug take-back program. If unavailable, mix the medicine with an undesirable substance before discarding it in household trash. Jodol is not recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jodol found in:

A-Z Index: